Gn Store Nord


Better-than-expected Q2; operational recovery in progress

21/08/25 -"GN’s Q2 performance surpassed market expectations. Although top-line growth was constrained by an uncertain macroeconomic environment, profitability improved significantly. GN’s recovery ..."

Pages
61
Language
English
Published on
21/08/25
You may also be interested by these reports :
21/08/25
GN’s Q2 performance surpassed market expectations. Although top-line growth was constrained by an uncertain macroeconomic environment, profitability ...

20/08/25
The Q2 results fell short of expectations and, consequently, the management downgraded its guidance for the second time this year. A subdued market ...

19/08/25
Coloplast reported Q3 2025 organic growth of 7%, driven by broad-based growth. EBIT before special items edged up 2% to DKK 1.915 billion, with a ...

13/08/25
Demant’s Q2 sales underperformed expectations, with top-line growth remaining flat. Growth in Hearing Care was offset by a decline in Diagnostics. ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO